RecruitingNCT07180992

Quantitative and Qualitative Monocytes Analysis and Their Impact on CART Cells Reponse in Multiple Myeloma

Sponsor

Centre Hospitalier Universitaire, Amiens

Enrollment

25 participants

Start Date

Jul 16, 2025

Study Type

OBSERVATIONAL

Conditions

Multiple Myeloma Monocytes CART Cells

Summary

Tumoral micro-environment in malignant haematological diseases, notably in multiple myeloma, is active on plasma cells survival and proliferation. Monocytosis and monocytes typing are described in multiple myeloma response as factors on proliferation and cell death evasion. CART cells have improved multiple myeloma care in last 5 years, nethertheless, early relapse occur and we must identify predictor factors of better response. The aim of this study is to analyze basic level and phenotyping of monocytes before and after CART cells infusion and study their impact on multiple myeloma response

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is examining the role of a type of immune cell called monocytes in people with multiple myeloma who are receiving CAR-T cell therapy. It aims to understand how these immune cells affect how well the CAR-T treatment works and how patients respond. **You may be eligible if...** - You are over 18 years old - You have been diagnosed with multiple myeloma - Your treatment plan includes CAR-T cell therapy - You are enrolled in the French social security system - You have agreed to participate in the study **You may NOT be eligible if...** - You have not consented to take part - You are not receiving CAR-T cell therapy as part of your myeloma treatment Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.